Methods for evaluating therapies and predicting clinical outcome related to coronary conditions

A method for predicting the clinical outcome for a patient after said patient has received therapy for an acute coronary syndrome, said method comprising the steps of:

• (a) detecting a first variable comprising an area of a serum creatine kinase-MB release curve as a function of time in said patient after initiation of said therapy;
• (b) detecting a second variable comprising a maxima of said serum creatine kinase-MB release curve in said patient after initiation of said therapy;
• then
• (c) generating a prediction of clinical outcome for said patient from said first and second variables, wherein said generating step is carried out with an empirically-based model of actual clinical experience;
• (d) detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy;
• and
• (e) generating a prediction of clinical outcome for said patient from said first, second, and third variables;
• wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope.

A method evaluating the efficacy of a potential therapeutic compound for an acute coronary syndrome, said method comprising

• (a) administering said potential therapeutic compound to a plurality of patients, and then
• (b) for each of said patients, generating a prediction of clinical outcome by:
• (i) detecting a first variable comprising an area of a serum creatine kinase-MB release curve as a function of time in said patient after initiation of said therapy;
• (ii) detecting a second variable comprising a maxima of said serum creatine kinase-MB release curve in said patient after initiation of said therapy;
• and then
• (iii) generating a prediction of clinical outcome for said patient from said first and second variables;
• then
• (c) compiling said prediction of clinical outcomes for said plurality of patients;
• and then
• (d) determining the efficacy of said potential therapeutic compound from said compiled predictions of clinical outcomes.

A method evaluating the efficacy of a potential therapeutic compound for an acute coronary syndrome, said method comprising

• (a) administering said potential therapeutic compound to a plurality of patients, and then
• (b) for each of said patients, generating a prediction of clinical outcome by:
• (i) detecting a first variable comprising an area of a serum creatine kinase-MB release curve as a function of time in said patient after initiation of said therapy;
• (ii) detecting a second variable comprising a maxima of said serum creatine kinase-MB release curve in said patient after initiation of said therapy;
• and then
• (iii) generating a prediction of clinical outcome for said patient from said first and second variables;
• then
• (c) compiling said prediction of clinical outcomes for said plurality of patients;
• and then
• (d) determining the efficacy of said potential therapeutic compound from said compiled predictions of clinical outcomes;
• (e) detecting a third variable comprising the slope of the descending portion of the serum creatine kinase-MB release curve after initiation of said therapy;
• and
• (f) generating a prediction of clinical outcome for said patient from said first, second, and third variables;
• wherein a steep slope for said descending portion is a more favorable indicator of clinical outcome than a shallow slope.